SecBot SecBot
PRESS-RELEASE ·Filed Aug 19, 2026

CMMB

Chemomab Therapeutics Ltd.
BEARISH
Impact 6/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS miss is significant for a micro-cap biotech, but the merger with Scipher Medicine is the primary catalyst. Monitor for merger closing updates and any regulatory milestones for nebokitug in RA. The stock's low liquidity and high volatility warrant caution.

DirectionBearish
Confidencehigh
Horizonmonths

nebokitug

◆ Mixed Named in this press release
Impact
Phase
Phase 2 (complete); preparing Phase 3
Time to market
At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
Next catalyst
None dated

What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.09
T+0 close · Aug 19, 2026 · via day close
Latest settled
−33.01%
T+60 · $1.40
Vs SPY
−31.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $2.09entry
  2. T+1 · 3mo ago −0.96%α −0.12% · $2.07
  3. T+5 · 3mo ago +23.92%α +24.31% · $2.59
  4. T+20 · 2mo ago +33.97%α +35.92% · $2.80
  5. T+60 · 5d ago −33.01%α −31.46% · $1.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned merger with Scipher Medicine to advance nebokitug into a Phase 2 RA trial is progressing, with closing expected by year-end. The significant EPS miss and lack of revenue highlight the pre-revenue clinical-stage nature of the company, but the merger catalyst provides a potential value inflection point.

Key Financial Metrics

EPS
−$0.24
est $0.00 · -51.8%
Rating
strong miss

Key Facts

  • Q1 2026 EPS of -$0.24 missed consensus of $0.00 by 51.8%
  • No revenue reported for the quarter
  • Planned merger with Scipher Medicine to assess nebokitug in Phase 2 RA trial continues, closing expected by year-end
  • Market cap of $14M with 88% analyst bullish rating

Financial Impact

EPS miss of -$0.24 vs $0 consensus; no revenue; merger value undisclosed

epsrevenue

Risk Factors

  • Merger may not close as expected
  • Nebokitug Phase 2 RA trial could fail
  • Cash burn without revenue may require dilutive financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3347616

Track record

15 reports on CMMB

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  2. Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  3. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  5. Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  6. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
  7. Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
  8. Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
  9. Aug 19, 202612w ago Press Release Bearish 6/10 Viewing Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
  10. Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026